TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Allergan is Laying Off 109 Employees in SoCal, Effective October 23 August 28, 2017 Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Conference August 30, 2017 Deal Spree Continues as Celgene Nabs Juno in $9B Deal January 21, 2018
Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Conference August 30, 2017